Okogen is developing a novel ophthalmic anti-infective treatment for acute infectious conjunctivitis, targeting both bacterial and adenoviral infections through a single therapeutic approach. This addresses the lack of approved treatments for adenoviral conjunctivitis, which constitutes over 90% of viral ocular infections and represents a significant gap in the current $4.2 billion conjunctivitis market.
Funding
$13.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Acute infectious conjunctivitis, commonly known as pink eye, affects millions worldwide, with a significant portion caused by adenoviruses for which there are currently no approved treatments. The current standard of care often involves broad-spectrum antibiotics, even though most cases are viral, contributing to antibiotic resistance and failing to address the underlying viral infection. This gap in treatment options leaves a substantial portion of patients without targeted relief.
Solution
Okogen is developing OKG-0301, a novel ophthalmic therapeutic designed to treat both bacterial and adenoviral acute infectious conjunctivitis. This single therapeutic approach aims to address the entire spectrum of acute infectious conjunctivitis, reducing the need for differential diagnosis and potentially minimizing the overuse of antibiotics. By targeting both bacterial and viral etiologies, Okogen seeks to provide a comprehensive solution for patients suffering from pink eye, improving treatment outcomes and reducing the burden of this common infection. OKG-0301 is currently in Phase 2B clinical trials.
Target Audience
The primary target audience includes individuals affected by acute infectious conjunctivitis, as well as ophthalmologists and primary care physicians seeking a comprehensive treatment option for this common condition.
Features
- Broad-spectrum anti-infective activity against both bacterial and adenoviral strains
- Single therapeutic approach eliminates the need for differential diagnosis in most cases
- Topical ophthalmic formulation for direct delivery to the site of infection
- Designed to reduce the overuse of antibiotics in viral conjunctivitis cases
- Clinical validation in Phase 2B trials demonstrating safety and efficacy